<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01760083</url>
  </required_header>
  <id_info>
    <org_study_id>2011-005905-64</org_study_id>
    <nct_id>NCT01760083</nct_id>
  </id_info>
  <brief_title>A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions</brief_title>
  <acronym>EuroCTO</acronym>
  <official_title>A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Euro CTO Club</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biosensors International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asahi Intecc Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Euro CTO Club</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CTOs are common among patients with angina, and are detected in around 20% of patients
      undergoing coronary angiography. Treatment of CTO has been found to constitute only 7% of PCI
      practice on average. One of the reasons for the under-presentation of CTOs in PCI target
      lesions is the lack of evidence-based medical data on treatment indications, and the
      continued low level of accepted evidence for the treatment of CTOs by PCI in PCI guidelines.

      Patients with a CTO represent patients with stable coronary artery disease. The COURAGE trial
      comparing PCI with optimal medical therapy in stable coronary disease did not show a
      difference in mortality or myocardial infarction between the two treatment options. However,
      CTOs were not included in the COURAGE trial. But that trial did confirm the superiority of
      PCI over OMT in controlling symptoms of angina, with a high cross-over rate to PCI. Whether
      PCI for CTO is superior to OMT in reducing MACE in those patients with a large ischaemic
      burden has never been tested in a randomized controlled trial.

      While there is compelling evidence from registry studies of a clinical and prognostic benefit
      following successful PCI of CTO compared with PCI failure, there has been no randomized
      controlled trial of contemporary PCI using drug-eluting stents versus optimal medical
      therapy. The COURAGE trial nuclear sub-study confirms both that prognosis is closely related
      to the extent of residual ischaemia and that PCI is more effective in reducing residual
      ischaemia than optimal medical therapy alone. This confirms earlier retrospective data
      suggesting that the benefit of PCI is greatest in patients with moderate (10-20%) or severe
      (&gt;20%) ischaemia.

      Study hypothesis: PCI with Biolimus eluting stent implantation plus OMT will be superior to
      OMT alone in improving health status at 12-month follow-up, and will be noninferior with
      respect to the composite of all cause death/ non fatal MI at 36-month follow up, in patients
      with a CTO in an epicardial coronary artery &gt;2.5 mm diameter and chronic stable angina with
      evidence of ischemia and viability in the territory subtended by the CTO
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Seattle Angina Questionnaire and EQ-5D for health outcomes measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major cardiovascular events</measure>
    <time_frame>36 months</time_frame>
    <description>Cumulative composite endpoint of all-cause death, non-fatal MI at 3 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and efficacy endpoints</measure>
    <time_frame>12 and 36 months</time_frame>
    <description>All cause mortality Cardiac mortality Myocardial Infarction Any hospitalization due to cardiovascular events (angina, congestive heart failure, arrythmias)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prcedural complications</measure>
    <time_frame>baseline upto 36 months</time_frame>
    <description>Incl. periprocedural enzyme leak (defined by CK increase &gt;3 times ULN); pericprocedural MI (new Q-wave or STEMI); pericardial tamponade, need for urgent CABG, CIN, death within 30 days, proven periprocedural cerebrovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol adherence</measure>
    <time_frame>36 months</time_frame>
    <description>Need to cross from OMT to PCI in Group 2 (after escalation up to maximum tolerated anti-anginal therapy and persistent unequivocal symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per protocol analysis</measure>
    <time_frame>36 months</time_frame>
    <description>primary endpoint comparison in patients who did have a successful revascularization compared to those patients treated medically who had no subsequent PCI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health-economic analysis</measure>
    <time_frame>12 and 36 months</time_frame>
    <description>Economic assessment &amp; cost efficacy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Chronic Stable Angina</condition>
  <condition>Dyspnea</condition>
  <condition>Coronary Occlusion</condition>
  <arm_group>
    <arm_group_label>Biolimus-eluting stent implantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCI of CTO using a Biomatrix drug-eluting stent system + optimal medical therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Optimal medical therapy. Subsequent PCI only if symptoms of angina persist despite optimal medical therapy. At least 2 anti-anginal agents or the maximum tolerated anti-anginal therapy should be used before crossover. Medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biolimus-eluting stent implantation</intervention_name>
    <description>Recanalization of chronic coronary artery occlusion and subsequent implantation of one or ore Biosensor stents</description>
    <arm_group_label>Biolimus-eluting stent implantation</arm_group_label>
    <other_name>Biosensors Biolimus-eluting stents of all sizes and lengths</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age with written informed consent

          -  CTO in native coronary artery

          -  a) Stable angina, or b) myocardial ischaemia in a territory supplied by CTO, and c)
             viability in akinetic myocardium (&lt;50% transmural late enhancement on MRI or normal
             resting perfusion scan)

          -  CTO located in segments 1-3 (RCA), 6-7 (LAD), 11-12 (LCx)

          -  target artery ≥2.5mm

        Exclusion Criteria:

          -  AMI or NSTE-ACS within 1 month

          -  Significant untreated coronary stenosis in a territory other than CTO

          -  Patients with MVD and significant non-CTO stenoses where it is deemed unsafe to treat
             the non-CTO lesion first (e.g. Significant proximal LAD lesion with chronically
             occluded RCA)

          -  Patient unsuitable for 12 month dual anti-platelet therapy

          -  Any exclusion criteria for PCI or DES

          -  Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year
             following index procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald S Werner, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Darmstadt, Darmstadt Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Saint-Augustin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33074</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Lagny</name>
      <address>
        <city>Lagny</city>
        <zip>77405</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Hospitalier Jacques Cartier - ICPS</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rangueil university hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka</name>
      <address>
        <city>Bad Berka</city>
        <zip>99438</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-Zentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Main Taunus Kliniken</name>
      <address>
        <city>Bad Soden</city>
        <zip>65812</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Catheterization Laboratory and Cardiovascular Interventional Unit Cannizzaro Hospita</name>
      <address>
        <city>Catania</city>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latvian Center of Cardiology Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Cardiología Intervencionista Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Villaroel</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Galdakao-Usansolo</name>
      <address>
        <city>Galdakao</city>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute - Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital - Brighton and Sussex University Hospitals</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiovascular Sciences University of Leicester</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart and Lung Institute Imperial College</name>
      <address>
        <city>London</city>
        <zip>SW7 2AZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://eurocto.eu</url>
    <description>Sponsor European CTO Club e.V. (ECC)</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2013</study_first_submitted>
  <study_first_submitted_qc>January 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2013</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

